Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.030
Sell
RSI(14)
40.485
Neutral
STOCH(KDJ)(9,3,3)
25.386
Neutral
ATR(14)
0.098
Low Volatility
CCI(14)
-75.348
Neutral
Williams %R
80.000
Sell
TRIX(12,20)
-0.467
Sell
StochRSI(14)
100.000
Buy
Search
Lipocine Inc
LPCNAdd to Watchlist
2.120USD
+0.010+0.47%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.85MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.47%
5 Days
+1.92%
1 Month
-17.19%
6 Months
-76.44%
Year to Date
-73.60%
1 Year
-34.37%
Key Figures
2.160Open
2.160High
29.43KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.39%Turnover Ratio
2.110Prev. Close
2.100Low
38.78KTurnover
1897.42P/E Static
0.69P/B
0.00%Div Yield TTM
-49.87%ROA
12.37052wk High
0.76Volume Ratio
8.35KNet Profit
7.48MShares
-1.9586EPS TTM
1.10Beta
-54.41%ROE
2.52052wk Low
2.84%Amplitude
100.00%Gross Margin
15.85MMarket Cap
-2.58Reward/Risk
4.54%Risk Rate
TradingKey Stock Score of Lipocine Inc
Currency: USD Updated: 2026-07-31Key Insights
Lipocine Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 167 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lipocine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lipocine Inc Highlights
StrengthsRisks
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.98M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -1.08, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.08M shares, increasing 42.40% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.62.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+189.86%
Upside Space
Lipocine Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+189.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Lipocine Inc
LPCN
2
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.116
Buy
MA10
2.142
Sell
MA20
2.261
Sell
MA50
2.276
Sell
MA100
3.206
Sell
MA200
4.587
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lipocine Inc Info
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Ticker SymbolLPCN
CompanyLipocine Inc
CEOPatel (Mahesh V)
Websitehttps://www.lipocine.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Lipocine Inc (LPCN)?
The current price of Lipocine Inc (LPCN) is 2.13.
What is the symbol of Lipocine Inc?
The ticker symbol of Lipocine Inc is LPCN.
What is the 52-week high of Lipocine Inc?
The 52-week high of Lipocine Inc is 12.37.
What is the 52-week low of Lipocine Inc?
The 52-week low of Lipocine Inc is 2.52.
What is the market capitalization of Lipocine Inc?
The market capitalization of Lipocine Inc is 15.92M.
Is Lipocine Inc (LPCN) currently rated as Buy, Hold, or Sell?
According to analysts, Lipocine Inc (LPCN) has an overall rating of Buy, with a price target of 6.00.
What is the Earnings Per Share (EPS TTM) of Lipocine Inc (LPCN)?
The Earnings Per Share (EPS TTM) of Lipocine Inc (LPCN) is -1.77.